These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 12406902

  • 1. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.
    Blood; 2003 Feb 15; 101(4):1494-504. PubMed ID: 12406902
    [Abstract] [Full Text] [Related]

  • 2. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2004 Mar 15; 103(6):2266-75. PubMed ID: 14604974
    [Abstract] [Full Text] [Related]

  • 3. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 15; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 4. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
    Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC.
    Blood; 2002 Oct 15; 100(8):2941-9. PubMed ID: 12351406
    [Abstract] [Full Text] [Related]

  • 5. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
    Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2005 May 01; 105(9):3679-85. PubMed ID: 15626738
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.
    J Biol Chem; 2003 Aug 29; 278(35):32892-8. PubMed ID: 12815052
    [Abstract] [Full Text] [Related]

  • 8. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R, Miething C, Thiede C, Peschel C, Duyster J.
    Blood; 2005 Jun 15; 105(12):4792-9. PubMed ID: 15718420
    [Abstract] [Full Text] [Related]

  • 9. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
    Spiekermann K, Faber F, Voswinckel R, Hiddemann W.
    Exp Hematol; 2002 Jul 15; 30(7):767-73. PubMed ID: 12135675
    [Abstract] [Full Text] [Related]

  • 10. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D.
    Blood; 2002 Jun 01; 99(11):3885-91. PubMed ID: 12010785
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.
    Leukemia; 2002 Oct 01; 16(10):2027-36. PubMed ID: 12357354
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
    Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S.
    Blood; 2002 Nov 01; 100(9):3423-5. PubMed ID: 12384447
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 16. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
    Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D.
    Blood; 2004 Sep 15; 104(6):1841-9. PubMed ID: 15166029
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 20. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.
    Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T.
    Oncogene; 2000 Feb 03; 19(5):624-31. PubMed ID: 10698507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.